FibroGen, Inc.'s (NASDAQ:FGEN) Stock Has Plunged to US$12.87, but Insiders May Have Sold Too Soon at an Even Lower Price of US$11.58
FibroGen, Inc.'s (NASDAQ:FGEN) Stock Has Plunged to US$12.87, but Insiders May Have Sold Too Soon at an Even Lower Price of US$11.58
Even though FibroGen, Inc. (NASDAQ:FGEN) has fallen by 5.9% over the past week , insiders who sold US$152k worth of stock over the past year have had less luck. Insiders would probably have been better off holding on to their shares given that the average selling price of US$11.58 is still lower than the current share price.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
View our latest analysis for FibroGen
FibroGen Insider Transactions Over The Last Year
In the last twelve months, the biggest single sale by an insider was when the insider, Thomas Kearns, sold US$152k worth of shares at a price of US$11.58 per share. That means that an insider was selling shares at slightly below the current price (US$12.87). When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. This single sale was just 5.1% of Thomas Kearns's stake. Thomas Kearns was the only individual insider to sell shares in the last twelve months.
The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
NasdaqGS:FGEN Insider Trading Volume August 31st 2022For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership Of FibroGen
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. FibroGen insiders own about US$18m worth of shares. That equates to 1.5% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
What Might The Insider Transactions At FibroGen Tell Us?
It doesn't really mean much that no insider has traded FibroGen shares in the last quarter. Our analysis of FibroGen insider transactions leaves us cautious. But we do like the fact that insiders own a fair chunk of the company. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. While conducting our analysis, we found that FibroGen has 1 warning sign and it would be unwise to ignore it.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
即使FibroGen公司納斯達克(Sequoia Capital:FDEN)在過去一週下跌了5.9%,但在過去一年裏拋售了價值15.2萬美元股票的內部人士運氣不佳。鑑於11.58美元的平均售價仍低於當前股價,內部人士可能會更好地持有自己的股票。
雖然我們永遠不會建議投資者完全根據公司董事的所作所為做出決定,但按照邏輯,你應該關注內部人士是在買入還是賣出股票。
查看我們對FibroGen的最新分析
FibroGen去年的內幕交易
在過去的12個月裏,內部人士最大的單筆出售是內部人士託馬斯·卡恩斯以每股11.58美元的價格出售了價值15.2萬美元的股票。這意味着一位內部人士以略低於當前價格(12.87美元)的價格出售股票。當內部人士以低於當前價格的價格出售股票時,這表明他們認為較低的價格是公平的。這讓我們想知道他們對最近(較高的)估值有何看法。然而,請注意,賣家可能有各種各樣的理由出售,所以我們不能確切地知道他們對股價的看法。這筆交易僅相當於託馬斯·卡恩斯所持股份的5.1%。託馬斯·卡恩斯是過去12個月中唯一一位出售股票的個人內部人士。
下面的圖表顯示了過去一年的內幕交易(按公司和個人)。如果你點擊圖表,你可以看到所有的個人交易,包括股票價格、個人和日期!
NasdaqGS:fgen內幕交易量2022年8月31日對於那些想要找到贏得投資這免費最近有內幕收購的不斷增長的公司名單可能就是合適的選擇。
FibroGen的內部所有權
我喜歡看內部人士在一家公司持有多少股份,以幫助我瞭解他們與內部人士的關係。通常,內部人持股越高,內部人就越有可能受到激勵,建立長期的公司。FibroGen內部人士擁有價值約1800萬美元的股票。這相當於該公司1.5%的股份。我們當然在其他地方看到了更高水平的內部人持股,但這些持股足以表明內部人和其他股東之間的關係。
FibroGen的內幕交易可能會告訴我們什麼?
上個季度沒有內部人士交易FibroGen的股票,這並不意味着什麼。我們對FibroGen內幕交易的分析讓我們保持謹慎。但我們確實喜歡這樣一個事實,即內部人士擁有公司的相當大一部分股份。因此,雖然瞭解內部人士在買入或賣出方面做了什麼是有幫助的,但瞭解一家特定公司面臨的風險也是有幫助的。在進行分析時,我們發現FibroGen1個警告標誌忽視它是不明智的。
當然了,如果你把目光投向別處,你可能會發現這是一筆很棒的投資。所以讓我們來看看這個免費有趣的公司名單。
就本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前負責公開市場交易和私人處置,但不包括衍生品交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧